Health
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United KingdomLONDON, April 30, 2026 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, announced it has been granted Innovation Passport designation for OTL-201, an investigational haemopoietic stem cell (HSC) gene therapy in development for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). The designation was awar
About this update from Kyowa Kirin Co., Ltd.
[{"type":"image","alt":"Orchard Therapeutics (Europe) Limited","displaySize":"","headline":null,"caption":"Orchard Therapeutics (Europe) Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":149,"url":"https://media.zenfs.com/en/globenewswire.com/f7c5ab86662cc16a57f6f696e0294e9f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5EXMgddkACQS2j3k5Q3MVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOQ--/https://media.zenfs.com/en/globenewswire.com/f7c5ab86662cc16a57f6f696e0294e9f","width":300,"height":149},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/5EXMgddkACQS2j3k5Q3MVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOQ--/https://media.zenfs.com/en/globenewswire.com/f7c5ab86662cc16a57f6f696e0294e9f","width":300,"height":149}},"lazy":false},{"type":"text","content":"Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom","length":172,"tagName":"p"},{"type":"text","content":"LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, announced it has been granted Innovation Passport designation for OTL-201, an investigational haemopoietic stem cell (HSC) gene therapy in development for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). The designation was awarded under the recently refreshed Innovative Licensing and Access Pathway (ILAP) in the UK, which provides a single integrated platform for sustained collaboration between developers, the Medicines and Healthcare products Regulatory Agency (MHRA), health technology assessment (HTA) authorities, and the National Health Service (NHS). The Innovation Passport is the entry point for companies to participate in ILAP.","length":742,"tagName":"p"},{"type":"text","content":"MPS-IIIA, also known as Sanfilippo syndrome type A, is a rare, fatal neurometabolic disorder caused by genetic mutations that lead to the toxic accumulation of heparan sulfate in the body. This results in a neurodegenerative disease characterised by progressive loss of cognitive and motor function. Children with MPS-IIIA rarely survive past adolescence, and there currently are no approved disease-modifying therapies to treat this disease.","length":442,"tagName":"p"},{"type":"text","content":"OTL-201 is one of three investigational therapies initially awa...